

In the Claims

Claims 1-17 (Cancelled)

Claim 18 (Previously presented): A cell culture comprising process-forming neuronal cells of the central nervous system; culture medium; and a solid substrate supporting said culture medium, wherein said neuronal cells lack processes and are clustered into one or more aggregates suspended in said culture medium, wherein there is no attachment of said neuronal cells to said substrate, and wherein said culture has a calcium concentration of 100 µM or less.

Claims 19-20 (Cancelled)

Claim 21 (Previously presented): The cell culture of claim 18, wherein said solid substrate comprises polystyrene and has an untreated surface for supporting said culture medium.

Claim 22 (Previously presented): The cell culture of claim 21, wherein said solid substrate is a culture vessel selected from the group consisting of a Petri dish, flask, bottle, plate, tube, and vial.

Claim 23 (Previously presented): The cell culture of claim 18, wherein said solid substrate comprises untreated plastic.

Claim 24 (Previously presented): The cell culture of claim 21, wherein said solid substrate is a microbiological plate.

Claim 25 (Previously presented): The cell culture of claim 18, wherein said solid substrate has a surface supporting said culture medium, and wherein said surface lacks charged molecules.

Claim 26 (Previously presented): The cell culture of claim 18, wherein said cell culture has a calcium concentration of 50 μM or less.

Claims 27-29 (Cancelled)

Claim 30 (Previously presented): The cell culture of claim 18, further comprising process-forming cells other than said neuronal cells.

Claim 31 (Previously presented): The cell culture of claim 18, further comprising non-process-forming cells.

Claim 32 (Cancelled)

Claim 33 (Previously presented): The cell culture of claim 18, wherein said culture medium lacks calcium ion as a formulated component.

Claim 34 (Previously presented): The cell culture of claim 18, wherein each of said one or more aggregates has an average diameter in the range of 150 μm to 200 μm .

Claim 35 (Previously presented): The cell culture of claim 18, wherein said neuronal cells within each of said one or more aggregates include living cells that remain viable *in vivo* upon implantation.

Claim 36 (Previously presented): The cell culture of claim 18, wherein said neuronal cells are fully differentiated.

Claim 37 (Previously presented): The cell culture of claim 18, wherein said neuronal cells are brain cells.

Claim 38 (Previously presented): The cell culture of claim 18, wherein said neuronal cells are human cells.

Claim 39 (Previously presented): A cell culture comprising process-forming neuronal cells of the central nervous system; and an untreated, polystyrene microbiological plate, wherein said neuronal cells lack processes, are supported by said plate, and are clustered into one or more aggregates, wherein there is no attachment of said neuronal cells to said plate, and wherein said culture has a calcium concentration of 100 μM or less.

Claim 40 (Withdrawn): A method for producing the cell culture of claim 18, comprising placing the neuronal cells on the solid substrate or culture medium; and culturing the neuronal cells for a period of time sufficient for said neuronal cells to cluster into said one or more aggregates.

Claim 41 (Withdrawn): A method for producing the cell culture of claim 39, comprising placing the neuronal cells on the plate; and culturing the neuronal cells for a period of time sufficient for said neuronal cells to cluster into said one or more aggregates.

Claim 42 (Withdrawn): A method for preparing process-forming neuronal cells for transplantation, comprising providing said cell culture of claim 18; removing said one or more aggregates from said culture; and combining said one or more aggregates with a pharmaceutically acceptable carrier.

Claim 43 (Withdrawn): A method for preparing process-forming neuronal cells for transplantation, comprising providing said cell culture of claim 39; removing said one or more aggregates from said culture; and combining said one or more aggregates with a pharmaceutically acceptable carrier.

Claim 44 (Previously presented): The cell culture of claim 18, wherein said neuronal cells are primary cells.

Claim 45 (Previously presented): The cell culture of claim 18, wherein said neuronal cells are cells of a cell line.

Claim 46 (Previously presented): The cell culture of claim 39, wherein said neuronal cells are primary cells.

Claim 47 (Previously presented): The cell culture of claim 39, wherein said neuronal cells are cells of a cell line.

Claim 48 (New): The cell culture of claim 18, wherein said neuronal cells are dopaminergic cells.

Claim 49 (New): The cell culture of claim 39, wherein said neuronal cells are dopaminergic cells.